Pure Biologics S.A. (WSE:PUR)

Market Cap	34.90M
Revenue (ttm)	-10.52M
Net Income (ttm)	-19.92M
Shares Out	3.75M
EPS (ttm)	-5.93
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,401
Average Volume	47,222
Open	9.30
Previous Close	9.31
Day's Range	9.20 - 9.62
52-Week Range	6.35 - 33.20
Beta	1.73
RSI	27.71
Earnings Date	Apr 16, 2025

About Pure Biologics

Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare neurological diseases. It is involved in the production, purification, analysis, and characterization of antibodies and aptamers; and design, development, and validation of assays, as well as conducts research on technology platforms for selecting active molecules. The company offers PureApta, a modular platform for in vitro selection of modified apta...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 51
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: PUR

Financial Performance

In 2023, Pure Biologics's revenue was 95,000, a decrease of -85.65% compared to the previous year's 662,000. Losses were -35.69 million, 39.4% more than in 2022.